707 related articles for article (PubMed ID: 30074820)
1. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.
Thompson SM; Garg I; Ehman EC; Sheedy SP; Bookwalter CA; Carter RE; Roberts LR; Venkatesh SK
Br J Radiol; 2018 Dec; 91(1092):20180345. PubMed ID: 30074820
[TBL] [Abstract][Full Text] [Related]
2. Assessment of factors affecting washout appearance of hepatocellular carcinoma on CT.
Hwang JA; Min JH; Kang TW; Jeong WK; Kim YK; Ko SE; Choi SY
Eur Radiol; 2021 Oct; 31(10):7760-7770. PubMed ID: 33856517
[TBL] [Abstract][Full Text] [Related]
3. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features.
Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM
J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging.
Yao S; Wei Y; Ye Z; Chen J; Duan T; Zhang Z; Song B
J Magn Reson Imaging; 2024 Jun; 59(6):2060-2070. PubMed ID: 34121266
[TBL] [Abstract][Full Text] [Related]
5. Imaging features of hepatocellular carcinoma in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: a systematic review and meta-analysis.
Park EJ; Son JH; Choi SH
Abdom Radiol (NY); 2022 Jun; 47(6):2089-2098. PubMed ID: 35389074
[TBL] [Abstract][Full Text] [Related]
6. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.
Ehman EC; Behr SC; Umetsu SE; Fidelman N; Yeh BM; Ferrell LD; Hope TA
Abdom Radiol (NY); 2016 May; 41(5):963-9. PubMed ID: 27193793
[TBL] [Abstract][Full Text] [Related]
7. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
[TBL] [Abstract][Full Text] [Related]
8. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?
Stocker D; Becker AS; Barth BK; Skawran S; Kaniewska M; Fischer MA; Donati O; Reiner CS
Eur Radiol; 2020 May; 30(5):2922-2933. PubMed ID: 32020398
[TBL] [Abstract][Full Text] [Related]
9. LI-RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Shin J; Lee S; Yoon JK; Chung YE; Choi JY; Park MS
J Magn Reson Imaging; 2021 Aug; 54(2):518-525. PubMed ID: 33638582
[TBL] [Abstract][Full Text] [Related]
10. Fat-containing hepatocellular carcinoma in patients with cirrhosis: proposal of a diagnostic modification regarding enhancement characteristics.
Delagnes A; Roux M; Vilgrain V; Guiu B; Laurent V; Sutter O; Bricault I; Trillaud H; Aubé C; Paisant A
Eur Radiol; 2024 Apr; 34(4):2283-2293. PubMed ID: 37816923
[TBL] [Abstract][Full Text] [Related]
11. Subtraction Images From Portal Venous Phase Gadoxetic Acid-Enhanced MRI for Observing Washout and Enhancing Capsule Features in LI-RADS Version 2018.
Chung JW; Yu JS; Choi JM; Cho ES; Kim JH; Chung JJ
AJR Am J Roentgenol; 2020 Jan; 214(1):72-80. PubMed ID: 31573851
[No Abstract] [Full Text] [Related]
12. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification.
Smereka P; Doshi AM; Lavelle LP; Shanbhogue K
AJR Am J Roentgenol; 2020 Aug; 215(2):382-389. PubMed ID: 32432909
[No Abstract] [Full Text] [Related]
13. Contrast-Enhanced Ultrasound With Perfluorobutane for Hepatocellular Carcinoma Diagnosis: Comparison of Imaging Phases and Diagnostic Criteria.
Kang HJ; Lee JM; Yoon JH; Yoo J; Kim JH; Park J
AJR Am J Roentgenol; 2024 Feb; 222(2):e2330156. PubMed ID: 37991335
[No Abstract] [Full Text] [Related]
14. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI.
Kang HJ; Lee JM; Jeon SK; Jang S; Park S; Joo I; Yoon JH; Han JK
Eur Radiol; 2021 Feb; 31(2):824-833. PubMed ID: 32845387
[TBL] [Abstract][Full Text] [Related]
15. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
16. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
[TBL] [Abstract][Full Text] [Related]
17. Gadoxetic Acid-enhanced MRI of Hepatocellular Carcinoma: Value of Washout in Transitional and Hepatobiliary Phases.
Kim DH; Choi SH; Kim SY; Kim MJ; Lee SS; Byun JH
Radiology; 2019 Jun; 291(3):651-657. PubMed ID: 30990381
[TBL] [Abstract][Full Text] [Related]
18. Multi-arterial phase MRI depicts inconsistent arterial phase hyperenhancement (APHE) subtypes in liver observations of patients at risk for hepatocellular carcinoma.
Cunha GM; Hasenstab KA; Delgado T; Ichikawa S; Lee MH; Dautt Medina PM; Kim SJ; Lee YH; Kwon H; Sirlin CB; Fowler KJ
Eur Radiol; 2021 Oct; 31(10):7594-7604. PubMed ID: 33876298
[TBL] [Abstract][Full Text] [Related]
19. Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS.
Hwang SH; Park S; Han K; Choi JY; Park YN; Park MS
Abdom Radiol (NY); 2019 Sep; 44(9):3078-3088. PubMed ID: 31165907
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
Huang Z; Zhou P; Li S; Li K
Eur Radiol; 2022 Oct; 32(10):7146-7154. PubMed ID: 35639147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
